These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

965 related items for PubMed ID: 29525327

  • 1. Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2.
    Packer M, Kitzman DW.
    JACC Heart Fail; 2018 Aug; 6(8):633-639. PubMed ID: 29525327
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
    Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Zannad F, Packer M, EMPEROR-Preserved Trial Committees and Investigators.
    Eur J Heart Fail; 2019 Oct; 21(10):1279-1287. PubMed ID: 31523904
    [Abstract] [Full Text] [Related]

  • 3. Derangements in adrenergic-adipokine signalling establish a neurohormonal basis for obesity-related heart failure with a preserved ejection fraction.
    Packer M.
    Eur J Heart Fail; 2018 May; 20(5):873-878. PubMed ID: 29493068
    [Abstract] [Full Text] [Related]

  • 4. First-in-class angiotensin receptor neprilysin inhibitor in heart failure.
    Vardeny O, Tacheny T, Solomon SD.
    Clin Pharmacol Ther; 2013 Oct; 94(4):445-8. PubMed ID: 23872864
    [Abstract] [Full Text] [Related]

  • 5. Neprilysin Inhibitors in Cardiovascular Disease.
    Kang G, Banerjee D.
    Curr Cardiol Rep; 2017 Feb; 19(2):16. PubMed ID: 28185171
    [Abstract] [Full Text] [Related]

  • 6. Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction.
    Peters AE, DeVore AD.
    Cardiol Clin; 2022 Nov; 40(4):473-489. PubMed ID: 36210132
    [Abstract] [Full Text] [Related]

  • 7. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA, Brown NJ.
    Circulation; 2016 Mar 15; 133(11):1115-24. PubMed ID: 26976916
    [Abstract] [Full Text] [Related]

  • 8. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
    Xiang B, Zhang R, Wu X, Zhou X.
    JAMA Netw Open; 2022 Sep 01; 5(9):e2231963. PubMed ID: 36125813
    [Abstract] [Full Text] [Related]

  • 9. Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity.
    Packer M.
    Circulation; 2018 Apr 10; 137(15):1614-1631. PubMed ID: 29632154
    [Abstract] [Full Text] [Related]

  • 10. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M.
    Lancet; 2020 Sep 19; 396(10254):819-829. PubMed ID: 32877652
    [Abstract] [Full Text] [Related]

  • 11. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
    Jhund PS, Claggett BL, Voors AA, Zile MR, Packer M, Pieske BM, Kraigher-Krainer E, Shah AM, Prescott MF, Shi V, Lefkowitz M, McMurray JJ, Solomon SD, PARAMOUNT Investigators.
    Circ Heart Fail; 2014 Nov 19; 7(6):953-9. PubMed ID: 25277997
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
    Packer M, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Anker SD, Zannad F, EMPEROR-Reduced Trial Committees and Investigators.
    Eur J Heart Fail; 2019 Oct 19; 21(10):1270-1278. PubMed ID: 31584231
    [Abstract] [Full Text] [Related]

  • 13. How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine.
    McMurray JJV, Packer M.
    Circulation; 2021 Mar 02; 143(9):875-877. PubMed ID: 33378214
    [No Abstract] [Full Text] [Related]

  • 14. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.
    Voors AA, Gori M, Liu LC, Claggett B, Zile MR, Pieske B, McMurray JJ, Packer M, Shi V, Lefkowitz MP, Solomon SD, PARAMOUNT Investigators.
    Eur J Heart Fail; 2015 May 02; 17(5):510-7. PubMed ID: 25657064
    [Abstract] [Full Text] [Related]

  • 15. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
    Jhund PS, Claggett B, Packer M, Zile MR, Voors AA, Pieske B, Lefkowitz M, Shi V, Bransford T, McMurray JJ, Solomon SD.
    Eur J Heart Fail; 2014 Jun 02; 16(6):671-7. PubMed ID: 24692284
    [Abstract] [Full Text] [Related]

  • 16. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan.
    Yang M, Butt JH, Kondo T, Jering KS, Docherty KF, Jhund PS, de Boer RA, Claggett BL, Desai AS, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Langkilde AM, Martinez FA, Petersson M, Shah SJ, Vaduganathan M, Wilderäng U, Solomon SD, McMurray JJV.
    Eur J Heart Fail; 2022 Dec 02; 24(12):2307-2319. PubMed ID: 36342375
    [Abstract] [Full Text] [Related]

  • 17. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial.
    Anker SD, Butler J, Filippatos G, Shahzeb Khan M, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Seronde MF, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M, EMPEROR-Preserved Trial Committees and Investigators.
    Eur J Heart Fail; 2020 Dec 02; 22(12):2383-2392. PubMed ID: 33251670
    [Abstract] [Full Text] [Related]

  • 18. Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction.
    Lyle MA, Iyer SR, Redfield MM, Reddy YNV, Felker GM, Cappola TP, Hernandez AF, Scott CG, Burnett JC, Pereira NL.
    JACC Heart Fail; 2020 Jan 02; 8(1):70-80. PubMed ID: 31392960
    [Abstract] [Full Text] [Related]

  • 19. Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.
    Macdonald PS.
    Clin Ther; 2015 Oct 01; 37(10):2199-205. PubMed ID: 26386501
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.